Publication Name	World Journal of Experimental Medicine
Manuscript ID	99968
Country	China

Received	2024-08-04 05:41
Peer-Review Started	2024-08-04 05:41
To Make the First Decision
Return for Revision	2024-09-19 04:42
Revised	2024-10-02 14:46
Second Decision	2024-10-16 02:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-10-16 10:35
Articles in Press	2024-10-16 10:35
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-10-26 00:35
Publish the Manuscript Online	2024-10-31 07:40

ISSN	2220-315x (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Genetics & Heredity
Manuscript Type	Letter to the Editor
Article Title	Familial hypercholesterolemia: Current limitations and future breakthroughs
Manuscript Source	Invited Manuscript
All Author List	Ze Xiang, Jia-Rui Li, Wei-Min Wan, Shu-Hui Li and Jian Wu
ORCID	Author(s) ORCID Number Jian Wu http://orcid.org/0000-0003-0087-3744
Funding Agency and Grant Number	Funding Agency Grant Number National Key Research and Development Program of China 2022YFE0209900
Corresponding Author	Jian Wu, MD, PhD, Professor, Department of Clinical Laboratory, Suzhou Municipal Hospital, No. 242 Guangji Road, Suzhou 215008, Jiangsu Province, China. wujianglinxing@163.com
Key Words	Familial hypercholesterolemia; Genetic mutations; Treatment; Limitations; Breakthroughs
Core Tip	Familial hypercholesterolemia (FH) is a genetic disorder characterized by significantly elevated levels of plasma low-density lipoprotein cholesterol, often leading to severe cardiovascular conditions such as acute myocardial infarction. Early detection, diagnosis, and treatment are crucial for improving patient outcomes. Despite growing awareness, over 90% of the estimated 30 million global FH cases remain undiagnosed, and many patients lack adequate treatment. Current management primarily involves statins, with additional therapies like Ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, though effectiveness varies, particularly in homozygous FH cases. Advancements in gene testing and precision medicine are essential for better understanding and treating FH. Future strategies include gene therapy and novel lipid-lowering drugs, alongside lifestyle modifications and genetic diagnosis for early intervention and improved prognosis.
Publish Date	2024-10-31 07:40
Citation	<p>Xiang Z, Li JR, Wan WM, Li SH, Wu J. Familial hypercholesterolemia: Current limitations and future breakthroughs. <i>World J Exp Med</i> 2024; 14(4): 99968</p>
URL	https://www.wjgnet.com/2220-315x/full/v14/i4/99968.htm
DOI	https://dx.doi.org/10.5493/wjem.v14.i4.99968

Full Article (PDF)	WJEM-14-99968-with-cover.pdf
Manuscript File	99968_Auto_Edited_142501.docx
Answering Reviewers	99968-answering-reviewers.pdf
Audio Core Tip	99968-audio.mp3
Conflict-of-Interest Disclosure Form	99968-conflict-of-interest-statement.pdf
Copyright License Agreement	99968-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	99968-foundation-statement.pdf
Peer-review Report	99968-peer-reviews.pdf
Scientific Editor Work List	99968-scientific-editor-work-list.pdf
CrossCheck Report	99968-crosscheck-report.pdf